NEWTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Wednesday, March 18, 2026, at 11:00 a.m. ET.